CN113861176A - 一种黄病毒抑制剂 - Google Patents
一种黄病毒抑制剂 Download PDFInfo
- Publication number
- CN113861176A CN113861176A CN202111146499.3A CN202111146499A CN113861176A CN 113861176 A CN113861176 A CN 113861176A CN 202111146499 A CN202111146499 A CN 202111146499A CN 113861176 A CN113861176 A CN 113861176A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- halogen
- hydroxy
- membered
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710831 Flavivirus Species 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 208000020329 Zika virus infectious disease Diseases 0.000 claims abstract description 10
- 208000001455 Zika Virus Infection Diseases 0.000 claims abstract description 7
- 208000035332 Zika virus disease Diseases 0.000 claims abstract description 7
- 206010054261 Flavivirus infection Diseases 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 229910052736 halogen Chemical group 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- -1 hydroxy, carboxy, formyl Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 241000907316 Zika virus Species 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 230000003441 anti-flavivirus Effects 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000004141 microcephaly Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000003152 Yellow Fever Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CZVKOBMHSGGZBN-UHFFFAOYSA-N 4-(4-bromophenoxy)butanenitrile Chemical compound BrC1=CC=C(OCCCC#N)C=C1 CZVKOBMHSGGZBN-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000256111 Aedes <genus> Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000546273 Lindera <angiosperm> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229940081066 picolinic acid Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- SPJREJSMKPMJCO-UHFFFAOYSA-N (4-aminothiophen-2-yl)boronic acid Chemical compound NC1=CSC(B(O)O)=C1 SPJREJSMKPMJCO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- JQDNCGRNPYKRAO-UHFFFAOYSA-N 2-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CC=N1 JQDNCGRNPYKRAO-UHFFFAOYSA-N 0.000 description 1
- PFKPRUNICVIARC-UHFFFAOYSA-N 3-(4-bromophenoxy)propan-1-ol Chemical compound OCCCOC1=CC=C(Br)C=C1 PFKPRUNICVIARC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 208000004293 Chikungunya Fever Diseases 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000004296 Zika fever Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000009560 cranial ultrasound Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及一种抑制黄病毒感染,尤其是寨卡病毒感染的化合物,以及该化合物在预防和治疗黄病毒感染,尤其是寨卡病毒感染引起的疾病方面的应用。
Description
技术领域
本发明属于化学药物领域,具体涉及一种对黄病毒属,尤其是寨卡病毒具有抑制活性的化合物,以及该该化合物在抗寨卡病毒感染方面的应用。
背景技术
组成黄病毒科的病毒包含至少3个可区别的属,包括温病毒属、黄病毒属和肝炎病毒属。尽管温病毒属造成许多在经济上中药的动物疾病,比如牛病毒性腹泻病毒、古典猪瘟病毒和羊边境病毒,它们在人疾病中的重要性很少被表征。黄病毒属会引起重要的人疾病,注入登革热和黄热病,寨卡病毒属黄病毒属,单股正链RNA病毒,直径20nm,是一种通过蚊虫进行传播的虫媒病毒,宿主不明确,主要在野生灵长类动物和栖息在树上的蚊子,如非洲伊蚊中循环。该病毒最早于1947年偶然通过黄热病监测网络在乌干达寨卡丛林的恒河猴中发现,随后于1952年在乌干达和坦桑尼亚人群中发现。该病毒活动一直比较隐匿,仅在赤道周围的非洲、美洲、亚洲和太平洋地区有寨卡病毒感染散发病例。最早一次暴发流行是2007年发生在西太平洋密克罗尼亚群岛的雅铺岛,更大的一次流行于2013年-2014年发生在大洋洲的法属波利尼西亚,感染了约32000人。伊蚊还传播黄病毒科中的另外三种病毒,包括登革热病毒、基孔肯雅病毒和黄热病毒,也主要在热带和亚热带地区流行。寨卡病毒病的潜伏期(从接触到出现症状的时间)尚不清楚,可能为数天。寨卡病毒感染者中,只有约20%会表现轻微症状,典型的症状包括急性起病的低热、斑丘疹、关节疼痛(主要累及手、足小关节)、结膜炎,其他症状包括肌痛、头痛、眼眶痛及无力。另外少见的症状包括腹痛、恶心、呕吐、黏膜溃疡和皮肤瘙痒。症状通常较温和,持续不到一周,需要住院治疗的严重病情并不常见。
然而,如果孕妇感染,胎儿可能会受到影响,导致新生儿小头症甚至死亡。2015年巴西的寨卡暴发流行中发现了很多小头畸形的新生儿(出生的新生儿头围与匹配的相同性别和孕龄的孩子比,低于平均值超过了两个标准差)。在2015年5月-2016年1月间,共报道4000例感染寨卡病毒的孕妇分娩了小头畸形儿,与往年小头畸形的比例相比,上升了20倍。35例小头畸形新生儿的头颅CT及头颅超声提示存在弥漫性脑组织钙化,主要发生在侧脑室旁,薄壁组织旁和丘脑区域、基底节区域。皮质和皮质下萎缩造成的脑室萎缩也能见到。小部分婴儿出现关节挛缩,提示周围和中枢神经系统受累。对寨卡疫情开展调查发现,越来越多的证据表明寨卡病毒与小头症之间存有关联。
寨卡病毒目前的地理分布范围与流行趋势预示着寨卡病毒具有潜在扩散的风险,作为一种新发传染病。目前,中国发现的寨卡病毒感染大几乎均为经口岸输入,尽管病例输入后进一步传播风险较低,但当前寨卡病毒在非洲、美洲和东南亚地区成上升态势,而且我国礼来与美非东南亚地区经贸合作密切,人员货物往来频繁,存在进一步跨境传播增加的风险。
目前没有特异性治疗方法,对症退热治疗可以使用对乙酰氨基酚。因此,开发对寨卡病毒有效的治疗药物十分必要。
发明内容
本发明的目的,在于提供一种全新的具有抑制寨卡病毒的化合物或其立体异构体或可药用盐,所述化合物具有如下结构:
其中,
A1选自氧、氮或硫;
A2选自O或S;
X选自氢、羟基或卤素;
R1或R2独立地选自氢、卤素、羟基、羧基、甲酰基、低级烷基、或任选被取代基组A取代的低级烷基;
取代基组A选自羟基、卤素、羰基、羰氧基、烷基羰基、烷氧基、甲酰基、羧基、氨基或取代的氨基、叠氮基、任选被取代的4-7元环烷基、任选被取代的4-7元杂环烷基、任选被取代的4-7元芳香环基、任选被取代的4-7元杂芳香环基。
一个具体的实施方案中,本发明具有如下结构式所示化合物
A1选自N、O或S,
X选自氢、羟基或卤素;
R2选自低级烷基、低级烃基、低级炔基、卤代低级烷基、环烷基、芳基、杂环基、芳基低级烷基、杂环基低级烷基、低级烷基氧基、卤代低级烷基氧基、低级烷基氧基低级烷基、低级烷基氧基低级烷基氧基、低级烷基羰基、低级烷基氧基羰基、低级烷基氨基、低级烷基羰基氨基、低级烷基氨基羰基、低级烷基磺酰基、低级烷基磺酰基氨基、羧基低级烷基氧基、芳基低级烷基氧基、叠氮基低级烷基、氰基低级烷基;
R3选自羟基、卤素、羰基、羰氧基、烷基羰基、烷氧基、甲酰基、羧基、氨基或取代的氨基、叠氮基、任选被取代的4-7元环烷基、任选被取代的4-7元杂环烷基、任选被取代的4-7元芳香环基、任选被取代的4-7元杂芳香环基。
一个具体的实施方案中,本发明具有如下结构式所示化合物
A1选自N、O或S,
X选自氢、羟基或卤素;
R3选自羟基、卤素、羰基、羰氧基、烷基羰基、烷氧基、甲酰基、羧基、氨基或取代的氨基、叠氮基、任选被取代的4-7元环烷基、任选被取代的4-7元杂环烷基、任选被取代的4-7元芳香环基、任选被取代的4-7元杂芳香环基;
R4选自卤素、羟基、羧基、氨基、叠氮基或氰基;
一个更为具体的实施方案中,本发明具有如下结构式所示化合物
其中X为氢、羟基或卤素;R3为羟基、卤素、羰基、羰氧基、烷基羰基、烷氧基、甲酰基、羧基、氨基或取代的氨基、任选被取代的4-7元环烷基、任选被取代的4-7元杂环烷基、任选被取代的4-7元芳香环基、任选被取代的4-7元杂芳环基;优选为芳香杂环,如芳香氮杂环;
R4选自叠氮基或氰基。
具体地,本发明涉及具有如下结构的化合物或其立体异构体或可要用盐,:
本发明还涉及一种药物组合物,包含本发明所述化合物或其药学上可接受的盐,以及药学上可接受的载体。
本发明公开内容的药物组合物可以通过口服、胃肠外或通过植入贮库进行给药。如再次使用的术语胃肠外包括皮下、皮内、静脉内、肌内、关节内、滑膜内、胸骨内、鞘内和损伤区注射或输液技术。
药物组合物可以以无菌可注射制剂的形式,例如,以无菌可注射含水或含油悬浮液的形式。可以根据本领域已知的技术使用合适的分散剂或润湿剂以及悬浮剂配置这种悬浮液。关于这些化合物的制备细节是本领域熟练技术人员已知的。
当口服给药时,本发明公开内容的药物组合物可以以任何口服可接受的剂型给药,所述剂型包括,但不限于,胶囊、片剂和含水混悬液和溶液。在口服运用片剂的情况中,通常使用的载体包括乳糖和玉米淀粉。还可以加入润滑剂如硬脂酸镁。对于以胶囊形式进行的口服给药,有用的载体/稀释剂包括乳糖、高和低分子量聚乙二醇和干玉米淀粉。当含水混悬液口服给药时,所述活性成分与乳化剂和混悬剂混合。如果需要的话,可以加入某些甜味剂和/或调味剂和/或着色剂。
用于上述组合物的其它适宜载体可以在标准药物教课书中找到,例如在“Remington’s Pharmaceutical Sciences”,19th ed.,Mack Publishing Company,Easton,Penn.,1995中。本领域技术人员已知所述公开内容的关于药物组合物的适宜递送形式的设计和制备的更多细节。
本发明中,除包含本发明所述化合物或其药学上可接受的盐外,还可以包含有其它抗黄病毒类化合物。
在用于预防和/或治疗流感病毒感染时,本发明公开内容中的化合物的剂量水平典型地在约1至约500毫克每千克(mg/kg)体重每日,更具体地说,在约1至约50mg/kg体重每日。典型地,本发明公开内容中的药物组合物可以每天给药约1次-约3次,优选地是流感发生前或发生后服用一次。或者作为连续输液的形式给药,这样的给药可以作为慢性或急性疗法使用。可以与载体材料混合以制备单一剂型的活性成分的数量将随所治疗的宿主和具体的给药方式而改变。
另一方面,本发明涉及一种制品或药盒,包含容器和包装插页,其中所述容器中装有本发明所述的具有本发明所述结构的化合物或其异构体或可药用盐,或包含本发明所述结构化合物的组合物,所述包装插页上载有药物的使用说明书。在一个优选的实施方案中,该制品或药盒进一步包含一个或多个容器,该容器中装有一种或多种预防或治疗黄病毒感染的其它抗病毒药物。
术语定义:
除非另有定义,本文使用的所有技术和科学术语具有与本发明所属领域的普通技术人员通常理解的相同的含义。
术语“未取代的”,当其用于限定某个基团时,意思是,该限定的基团没有为氢原子之外的其它基团所取代,此时该某个基团具有按照本发明所属领域的普通技术人员通常理解的相同含义。例如,未取代的杂环基,是指杂环上的氢原子没有被任何其它基团所取代,比如呋喃、吡啶、二氢吡啶等。
术语“取代的”,当其用于限定某个基团时,意思是,其限定的基团上的某1个、2个、3个或更多个氢原子被取代基的取代,1个、2个、3个或更多个氢原子,可以是同一个碳(或氮)原子上的氢原子,也可以是不同碳(或氮)上的氢原子,此时该某个基团的含义应结合取代基来理解,本发明中,除非特别说明,当提及“取代的”,意指有其由限定的基团中的氢原子由选自下列中的某一个、2个、3个或更多个取代基所取代:
氰基、卤素、羟基、羧基、酯基、酰胺基、磺酰胺基、胺基、甲酰基、低级烷基、低级烃基、低级炔基、卤代低级烷基、羟基取代的低级烷基、环烷基、芳基、杂环基、芳基低级烷基、杂环基低级烷基、低级烷基氧基、卤代低级烷基氧基、低级烷基氧基低级烷基、低级烷基氧基低级烷基氧基、低级烷基羰基、低级烷基氧基羰基、低级烷基氨基、低级烷基羰基氨基、低级烷基氨基羰基、低级烷基磺酰基、低级烷基磺酰基氨基、羧基低级烷基氧基、芳基低级烷基氧基。
在涉及到具体命名时,取代基通常置于被取代的基团之前,如“羧基亚甲基氧基”指氧基被亚甲基取代,二而亚甲基又被羧基取代,其结构可表示为:
术语“立体异构体”是指由分子中原子在空间上排列方式不同产生的异构体,包括顺反异构体、对映异构体和构象异构体。所有立体异构体均属于本发明的范围,本发明的化合物可以为单独立体异构体或其它异构体的混合物,如外消旋体,或者所有其它立体异构体的混合物。
术语“盐”是指本发明化合物与酸形成的药学上可接受的盐,如可以是有机或无机盐,比如选自:盐酸、硫酸、磷酸、硝酸、富马酸、柠檬酸、马来酸、苯磺酸、磺酸、苹果酸、琥珀酸、乳酸、乙酸、丙二酸等。
术语“烃基”包括烷基或烃基(如烯基或炔基)。
烷基是指直连或支链或环状的饱和的由碳和氢构成的取代基,低级烷基是指由1-6个碳原子构成的烷基。烯基是指直连或支链或环状的不饱和的由碳和氢构成的取代基,低级烯基是指由1-6个碳原子构成的烯基;炔基是指直连或支链的不饱和的由碳和氢构成的取代基,低级炔基是指由1-6个碳原子构成的炔基。取代的烷基(或取代的烃基)是指烷基上的一个或一个以上的氢原子被其它基团如卤素、羟基、羧基、氰基、环烷基、芳基、杂芳基、氧代、杂环烷氧基等取代。
术语“环烷基”指饱和或不饱和单环烃基,一般包含3-20个碳原子,环烷基可以是单环,也可以是螺环、桥环、稠环或并环。
术语芳基不仅包含碳环芳基,也包含杂环芳基。碳环芳基指6-10元全碳环或多环芳香基团,包括苯基、萘基、联苯基等,碳环芳基也可以是取代或未被取代的。杂环芳基是指含有至少一个杂原子的杂芳香体系基团,包括单环杂环芳基或稠环杂环芳基,杂原子选自氧、硫或氮,包括但不限于呋喃、噻吩、吡咯、噻唑等,杂芳基可以是取代或未被取代的。
术语“杂环基”是指至少含有一个杂原子的环烷基饱和或不饱和单环烃基
具体实施方式
以下列举本发明化合物的一般制造方法,另外,萃取、纯化等只要进行通常邮寄化学的实验中进行处理即可。
本发明化合物的合成可以参考本领域中公知的步骤进行实施。
原料化合物可以使用市售的化合物、本说明书中记载的化合物、本说明书中引用的文献中记载的化合物,和其它公知化合物。
本发明化合物中,可以存在互变异构体,本发明含有这些化合物,包含其所有可能的异构体和它们的混合物。
当欲获得本发明化合物的盐时,对于本发明的化合物,可以制备成适合的盐的形式。
各缩写的意思
MsCl:甲基磺酰氯
Et3N:三乙胺
DCM:二氯甲烷
EtOAc:乙酸乙酯
NaCN:氰化钠
NaN3:叠氮化钠
18-crown-6:18-冠-6
DMSO:二甲基亚砜
Na2CO3:碳酸钠
1,4-dioxane:1,4-二氧六环
PdCl2(PPh3)2:双(三苯基膦)氯化钯
MeOH:甲醇
DMF:N,N-二甲基甲酰胺
HATU:2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
DIPEA:N,N-二异丙基乙胺
实施例1:下式化合物的合成
化合物1的合成
500mL茄形瓶中3-(4-溴苯氧基)丙烷-1-醇(15.0g,64.9mmol)溶于120mL二氯甲烷,后加入三乙胺(7.2g,71.4mmol),冰浴降温至0℃,维持0℃滴加MsCl的二氯甲烷溶液(14.1g,68.1mmol in 30mL DCM),30min滴加完全,后自然升温至室温,反应过夜,加入水150mL淬灭反应,分液后有机相分别用水洗(100mL x 1),饱和食盐水洗(50mL x 1),无水硫酸钠干燥后减压浓缩,残余物正相柱层析分离,DCM/EtOAc体系洗脱,洗脱液减压浓缩得目标化合物(类白色固体,19.1g,95.1%)
ESI(310.0,312.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.40(d,2H),6.82(d,2H),4.42(t,2H),4.13(t,2H),3.22(s,3H),2.02(m,2H).
相似的操作过程应用于3-(4-溴-2-氟苯氧基)甲磺酸丙酯的合成,得类白色固体产物8.5g(96.3%)
ESI(327.0,329.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.40(m,1H),7.36(m,1H),6.78(m,1H),4.39(t,2H),4.12(t,2H),3.22(s,3H),2.11(m,2H).
100mL茄形瓶中加入3-(4-溴苯氧基)甲磺酸丙酯(3.4g,10.9mmol),DMSO(20mL),18-冠-6(0.3g)及NaCN(1.60g,32.6mmol),75℃下反应过夜,降温后倒入至200mL去离子水中,抽滤收集不溶物,后正相柱层析纯化,DCM/EtOAc洗脱,得类白色固体(1.68g,64.3%)。
ESI(240.0,242.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.38(d,2H),6.90(d,2H),4.11(t,2H),2.21(m,2H),1.98(m,2H).
相似的操作应用于
类白色固体,1.72g,61.5%。
ESI(258.0,260.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.36(m,2H),6.78(m,1H),4.00(t,2H),1.96-2.10(m,4H).
100mL茄形瓶中加入3-(4-溴苯氧基)甲磺酸丙酯(4.1g,13.3mmol),DMSO(30mL),18-冠-6(0.4g)及NaN3(1.04g,16.0mmol),50℃下反应过夜,降温后倒入至300mL去离子水中,抽滤收集不溶物,100mL纯化水洗涤滤饼,后正相柱层析纯化,DCM/EtOAc洗脱,得类白色固体(2.67g,78.6%)。
ESI(256.0,258.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.38(d,2H),6.90(d,2H),4.11(t,2H),2.21(m,2H),1.98(m,2H).
相似的操作应用于
类白色固体,2.47g,80.2%。
ESI(274.0,276.0,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 7.35(m,2H),6.84(m,1H),4.08(t,2H),1.75(m,2H),1.53(m,2H).
50mL茄形瓶中加入4-(4-溴苯氧基)丁腈(1.0g,4.2mmol)、(4-氨基噻吩-2-基)硼酸(655mg,4.6mmol)、碳酸钠(801mg,7.6mmol)二氧六环/水(20mL/1mL)及PdCl2(PPh3)2(295mg,0.42mmol),回流反应6h,后减压浓缩,残余物柱层析纯化,DCM/MeOH体系洗脱得淡黄色固体(470mg,43.4%)。
ESI(369.3,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 8.42(s,1H),7.55(d,2H),6.94(d,2H),6.27(s,1H),4.28(brs,2H),4.12(t,2H),2.12(m,2H),1.85(t,2H).
相似的操作应用于
淡黄色固体(342mg,38.6%)
ESI(277.1,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 8.40(s,1H),7.50(m,2H),7.24(m,1H),6.30(s,1H),4.57(brs,2H),4.03(t,2H),2.10(m,2H),1.88(t,2H).
淡黄色固体(408mg,41.5%)
ESI(275.2,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 8.40(s,1H),7.51(m,2H),7.24(m,1H),6.30(s,1H),4.57(brs,2H),4.03(t,2H),1.72(m,2H),1.47(t,2H).
淡黄色固体(277mg,29.8%)
ESI(293.2,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 8.25(s,1H),7.50(m,2H),7.28(m,1H),6.41(s,1H),4.77(brs,2H),4.14(t,2H),1.72(m,2H),1.48(t,2H).
25mL茄形瓶中加入4-(4-(4-氨基噻吩-2-基)苯氧基)丁腈(70mg,0.27mmol)、吡啶甲酸(37mg,0.30mmol)、HATU(114mg,0.30mmol)、DIPEA(42mg,0.32mmol)及无水DMF(5mL),N2保护下室温反应6h后减压浓缩,残余物Pre-TLC纯化,DCM/MeOH展板,得目标化合物(浅褐色固体,71mg,72.5%)
ESI(363.1,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 11.2(s,1H),8.72(d,1H),8.33(s,1H),8.37(s,1H),7.95(m,2H),7.76(d,2H),6.99(d,2H),6.33(s,1H),3.98(t,2H),2.12(m,2H),1.85(t,2H).
相似的操作,可用于合成如下结构化合物(化合物2至12):
化合物13的合成
25mL茄形瓶中加入4-(4-(4-氨基噻吩-2-基)苯氧基)丁腈(70mg,0.27mmol)、2-溴甲基吡啶氢溴酸盐(137mg,0.54mmol)、碳酸铯(264mg,0.81mmol)及无水DMF(5mL),N2保护下80℃反应8h后在DCM/水中分液,DCM反萃水相(15mL x 2),合并有机相,水洗涤(20mL x1),饱和食盐水洗涤(20mL x 1),无水硫酸钠干燥后减压浓缩,残余物Pre-TLC纯化,DCM/MeOH展板,得目标化合物(浅棕色固体,78mg,42.3%)
ESI(350.1,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 8.62(d,1H),8.24(s,1H),7.84(m,1H),7.78(br s 1H),7.70(m,2H),7.23(m,2H),7.01(d,2H),6.37(m,1H),4.83(s,2H),4.24(t,2H),1.85-2.10(m,4H).
类似的方法,可以合成化合物14至24。
实施例4化合物33的合成
50mL茄形瓶中加入4-(4-溴苯氧基)丁腈(1.0g,4.2mmol)、(4-氨基咪唑-2-基)硼酸(579mg,4.6mmol)、碳酸钠(801mg,7.6mmol)二氧六环/水(20mL/1mL)及PdCl2(PPh3)2(295mg,0.42mmol),回流反应6h,后减压浓缩,残余物柱层析纯化,DCM/MeOH体系洗脱得淡黄色固体(420mg,41.4%)。
ESI(242.2,[M+H]+),1H-NMR(400MHz,CDCl3):δppm 12.52(br s,1H),7.87(d,2H),7.10(d,2H),7.03(s,1H),6.58(br s,2H),6.52(d,1H),4.11(t,2H),2.21(m,2H),1.87(m,2H).
25mL茄形瓶中加入4-(4-(4-氨基咪唑-2-基)苯氧基)丁腈(0.27mmol)、吡啶甲酸(37mg,0.30mmol)、HATU(114mg,0.30mmol)、DIPEA(42mg,0.32mmol)及无水DMF(5mL),N2保护下室温反应6h后减压浓缩,残余物Pre-TLC纯化,DCM/MeOH展板,得目标化合物(浅褐色固体,9.8mg,10.5%)
ESI(346.2,[M+H]+),1H-NMR(400 MHz,CDCl3):δppm 12.32(br s,1H),10.52(brs,1H),8.82(d,1H),8.35(d,1H),8.10(m,1H),7.97(m,1H),7.88(d,2H),7.03(d,2H),7.04(d,1H),6.48(d,1H),4.13(t,2H),2.06(m,2H),1.87(t,2H)。
实施例5:化合物对寨卡病毒的抑制活性
所用试剂与材料:DMEM培养基、FBS、PBS、0.25%的胰蛋白酶,均为Thermo公司产品;DMSO、无水乙醇均为Sigma公司产品。
ZIKV MOI=1感染A549细胞,试验步骤如下:
1、种植细胞:在96孔细胞培养板中接种A549细胞,按8×103/孔接种,24小时后细胞长至单层(细胞覆盖孔底的面积约为90%),吸出培养基,接入寨卡病毒样品100μL,37℃吸附1小时,吸附完成后,吸弃各孔中的病毒液,用DMEM培养基洗去未吸附的病毒,加入用含5%胎牛血清的DMEM培养基稀释至指定浓度的各化合物,于37℃,5%CO2的培养箱中培养48小时,收集各个孔中的上清,再根据空斑试验检测病毒滴度。
空斑试验:采用ZIKV敏感的A549细胞进行空斑实验,即把A549细胞接种于24孔板,24h后依次接种400uL含2%FBS培养基10倍稀释的ZIKV上清液,稀释度为10-1至10-10,每个稀释度2个副孔,至于37℃,5%CO2培养箱培养吸附1h,然后加入600uL甲基纤维素覆盖液(含2%胎牛血清的DMEM),37℃,5%CO2培养箱培养,4-5天左右观察结果。
记录对病毒抑制情况,并计算EC50和EC90的浓度(结果见下表)。
化合物用DMSO溶解,按如下浓度梯度往下稀释,50μM、25μM、12.5μM、6.25μM、1μM、500nM、250nM、125nM、62.5nM、31.25nM。
当EC50或EC90介于50nM及以下时,活性计为A;EC50或EC90介于50~100nM时,活性计为B;当EC50或EC90介于100nM~1000nM范围时,活性计为C,当EC50或EC90介于1μM~10μM范围时,活性计为D,当EC50或EC90介于10μM~50μM范围时,活性计为E,当EC50或EC90大于50μM时,认为没有活性。结果见下表。
Claims (9)
2.具根据权利要求1所述的化合物或其立体异构体或可要用盐,有以下所示的化合物或其药学上可接受的盐,
A1选自N、O或S,
X选自氢、羟基或卤素;
R2选自低级烷基、低级烃基、低级炔基、卤代低级烷基、环烷基、芳基、杂环基、芳基低级烷基、杂环基低级烷基、低级烷基氧基、卤代低级烷基氧基、低级烷基氧基低级烷基、低级烷基氧基低级烷基氧基、低级烷基羰基、低级烷基氧基羰基、低级烷基氨基、低级烷基羰基氨基、低级烷基氨基羰基、低级烷基磺酰基、低级烷基磺酰基氨基、羧基低级烷基氧基、芳基低级烷基氧基、叠氮基低级烷基、氰基低级烷基;
R3选自羟基、卤素、羰基、羰氧基、烷基羰基、烷氧基、甲酰基、羧基、氨基或取代的氨基、叠氮基、任选被取代的4-7元环烷基、任选被取代的4-7元杂环烷基、任选被取代的4-7元芳香环基、任选被取代的4-7元杂芳香环基。
6.一种抗病毒药物组合物,所述组合物包含权利要求1-5中任意一权利要求所述化合物或其立体异构体或可要用盐的组合物,以及至少一种选自核苷类化合物或其它抗黄病毒(尤其是寨卡病毒)的药物。
7.包含权利要求1-5中任意一权利要求所述化合物或其药学上可接受的盐,以及药学上可接受的载体的药剂。
8.权利要求1-5中任意一权利要求所述化合物或其药学上可接受的盐在制备具有预防或治疗黄病毒感染(尤其是寨卡病毒感染)的药物中的应用。
9.一种制品或药盒,包含容器和包装插页,其中所述容器中装有权利要求1-5中任意一权利要求所述的化合物或其药学上可接受的盐、或权利要求6所述的组合物、或权利要求7所述的药剂,所述包装插页上载有药物的使用说明书。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111146499.3A CN113861176B (zh) | 2021-09-28 | 2021-09-28 | 一种黄病毒抑制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111146499.3A CN113861176B (zh) | 2021-09-28 | 2021-09-28 | 一种黄病毒抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113861176A true CN113861176A (zh) | 2021-12-31 |
CN113861176B CN113861176B (zh) | 2023-11-03 |
Family
ID=78992327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111146499.3A Active CN113861176B (zh) | 2021-09-28 | 2021-09-28 | 一种黄病毒抑制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113861176B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1795190A (zh) * | 2002-12-10 | 2006-06-28 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物及方法 |
CN102718744A (zh) * | 2005-05-13 | 2012-10-10 | Viro化学制药公司 | 治疗或预防黄病毒感染的组合物和方法 |
US20120309701A1 (en) * | 2009-10-22 | 2012-12-06 | The Washington University | Compounds and methods for treating bacterial infections |
CN105517999A (zh) * | 2013-07-11 | 2016-04-20 | 百时美施贵宝公司 | Ido抑制剂 |
WO2019107662A1 (ko) * | 2017-11-30 | 2019-06-06 | 한국해양과학기술원 | 신규한 티에노[3,2-b]피리딘-5(4H)-온 유도체 화합물, 이의 제조방법 및 이의 용도 |
-
2021
- 2021-09-28 CN CN202111146499.3A patent/CN113861176B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1795190A (zh) * | 2002-12-10 | 2006-06-28 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物及方法 |
CN102718744A (zh) * | 2005-05-13 | 2012-10-10 | Viro化学制药公司 | 治疗或预防黄病毒感染的组合物和方法 |
US20120309701A1 (en) * | 2009-10-22 | 2012-12-06 | The Washington University | Compounds and methods for treating bacterial infections |
CN105517999A (zh) * | 2013-07-11 | 2016-04-20 | 百时美施贵宝公司 | Ido抑制剂 |
WO2019107662A1 (ko) * | 2017-11-30 | 2019-06-06 | 한국해양과학기술원 | 신규한 티에노[3,2-b]피리딘-5(4H)-온 유도체 화합물, 이의 제조방법 및 이의 용도 |
Non-Patent Citations (4)
Title |
---|
ABDILLAHI ET AL.: "Synthesis of Novel 2-Thienylimino-1,3-thiazolidin-4-ones", 《SYNTHESIS》, no. 15, pages 2543 - 2546 * |
DAN-BI SUNG ET AL.: "Synthesis, Molecular Engineering, and Photophysical Properties of Fluorescent Thieno[3,2‑b]pyridine-5(4H)‑ones", 《THE JOURNAL OF ORGANIC CHEMISTRY》, vol. 84, pages 379 - 391 * |
J. HENNING SAHNER ET AL.: "Exploring the chemical space of ureidothiophene-2-carboxylic acids as inhibitors of the quorum sensing enzyme PqsD from Pseudomonas aeruginosa", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 96, pages 14 - 21, XP029168183, DOI: 10.1016/j.ejmech.2015.04.007 * |
JONG SEOK LEE ET AL.: "Reactions of 3‐methylamino‐5‐phenylthiophene with α,β‐unsaturated esters and α,β‐unsaturated nitriles", 《J. HETEROCYCLIC CHEM.》, vol. 37, pages 363 - 372 * |
Also Published As
Publication number | Publication date |
---|---|
CN113861176B (zh) | 2023-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3180319B1 (en) | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
JP2021534133A (ja) | ケトアミド系化合物およびその調製方法、医薬組成物および用途 | |
JP2023535701A (ja) | 抗ウイルス剤としての官能化ペプチド | |
WO2021027911A1 (zh) | 新型螺环类K-Ras G12C抑制剂 | |
CN109071447A (zh) | 四环吡啶酮化合物作为抗病毒剂 | |
CN108976223B (zh) | 稠合三环类化合物及其在药物中的应用 | |
WO2005067900A2 (en) | Azabenzofuran substituted thioureas as inhibitors of viral replication | |
WO2005095345A2 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
JP2023537402A (ja) | 抗ウイルス剤としての機能化ペプチド | |
CN102656164A (zh) | 作为结核病抑制剂的嘧啶化合物 | |
EP2621916B1 (en) | Benzazole derivatives as histamine h4 receptor ligands | |
JP2007523868A (ja) | ウイルス複製の阻害薬として有用な置換アリールチオウレア誘導体類 | |
JP6041877B2 (ja) | キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用 | |
WO2023033098A1 (ja) | ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 | |
KR102650441B1 (ko) | 내부 사이클릭 설피아미딘 아미드-아릴 아미드 화합물 및 이의 b형 간염 치료를 위한 용도 | |
JPH0674264B2 (ja) | 1―(ピリジニルアミノ)―2―ピロリジノンおよびその製造法 | |
JP2023145644A (ja) | ジヒドロイソキノリン系化合物 | |
CN113861176A (zh) | 一种黄病毒抑制剂 | |
JP2021529159A (ja) | N−置換テトラヒドロチエノピリジン誘導体及びその使用 | |
JPH11514656A (ja) | 5ht▲下1b▼活性を有するアザスピロ誘導体 | |
CN106674245B (zh) | 吡喃葡萄糖基衍生物的制备及医药上的应用 | |
TW200526205A (en) | Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient | |
CN107207477B (zh) | 用于治疗病毒性疾病的亚氨基糖 | |
JP7454729B2 (ja) | 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物 | |
EP3091013B1 (en) | 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |